March 2025: PatientView’s ‘Patients in Action’ survey which ran from June to August 2024 attracted responses from 1,144 patient groups (drawn from 83 countries, and from 65 broad specialties). 39… Continue reading “Patients in Action—a focus on breast cancer patient groups”
January 2025: Health Technology Assessments (HTAs) systematically evaluate the properties, impacts, and effects of treatments or medical devices to guide decisions on their adoption, use, or reimbursement. They address medical,… Continue reading “Patient Groups and Health Technology Assessments (HTAs)”
December 2024: A new systematic analysis from PatientView identifying specific strategic steps that pharma needs to take to improve its reputation. PatientView’s annual ‘Corporate Reputation of Pharma’ assesses the performance… Continue reading “How Pharma needs to improve, according to patient groups in Asia-Pacific”
November 2024: Over the past 40 years, the role of patient groups has undergone a radical transformation. Historically, patients—and the groups representing them—had minimal influence on their healthcare systems, frequently… Continue reading “Patients in Action”
July 2024: The field of oncology, cancer research and cancer treatment has seen continued investment over the last few years. In the UK, cancer incidence rates are projected to rise… Continue reading “PatientView’s Corporate Reputation of Pharma 2023/24: Insights from Specialised Cancer Patient Groups”
June 2024: In recent decades, patient groups have become increasingly integrated into today’s healthcare landscape. Due to their unique understanding of patient needs, these groups have emerged as central figures… Continue reading “New survey: Are patient groups considered essential stakeholders to the healthcare system?”
May 2024: Links between pharmaceutical companies and patient groups are becoming increasingly common. Back in 2017, 61% of patient groups responding to that year’s ‘Corporate Reputation of Pharma’ survey mentioned… Continue reading “What do Pharma companies find valuable in relationships with patient groups?”
February 2024: As election year in the USA begins to ramp up, the pharma industry will be a likely topic on the political frontlines. Media headlines and campaign pledges can… Continue reading “In an election year, what do US patient groups think about how pharma should improve?”
February 2024: Patient groups have a wealth of experience in the diseases and conditions in which they specialise—at least from a patient perspective. From this standpoint, these groups have traditionally… Continue reading “The growing role of patient groups in healthcare research”
December 2023: At first glance, the ‘Environmental, Social and Governance’ (ESG) practices of the pharmaceutical industry can seem a subject far removed from the concerns of patients. This view has… Continue reading “Why should patients be interested in pharma’s ESG activities?”
